Search

A total of 463 first void urine specimens were obtained from patients attending the Sexually Transmitted Diseases (STD) Outpatients Clinic of the St. Orsola University Hospital in Bologna, Italy. Samples were tested by the new test VERSANT® CT/GC DNA 1.0 Assay (Siemens Healthcare Diagnostics Inc.), a multiplex Real-Time Polymerase Chain Reaction (PCR) assay, for simultaneous detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC).A total of two specimens were collected from each patient, respectively: one urine sample for VERSANT® CT/GC DNA 1.0 Assay testing and one urethral or endocervical swab for the detection of C. trachomatis by IDEIA™ PCE Chlamydia (Oxoid). In our population, the prevalence of CT in patients was 11.9%, when studied by VERSANT® CT/GC DNA 1.0 Assay, whereas it was only 5.0%, when samples where analyzed by IDEIA™ PCE Chlamydia. In conclusion,VERSANT® CT/GC DNA 1.0 Assay demonstrated to be a highly sensitive and specific technique for the detection of CT in patients attending a STD Clinic. Nucleic acid amplifications tests are the most sensitive assays available to date for CT and GC in clinical specimens and this new Real-Time PCR assay adds to the group of commercially available assays that are available to laboratories as choices for superior diagnostic performance.

Laboratory diagnosis of toxoplasmosis is mainly based on serological methods, particularly important in the most challenging situations, as the diagnosis of primary infection during pregnancy and diagnosis of congenital infection. Tests for the detection of IgA antibodies are especially important in the newborns, because they are more sensitive than IgM conventional methods. The purpose of this study was to evaluate diagnostic performances of Enzygnost system for IgA detection, achieved by using Enzygnost Anti-human IgA/POD conjugate in combination with Enzygnost toxoplasmosis IgG (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). A retrospective study was performed with 591 serum samples submitted to the Microbiology Laboratory of S. Orsola Hospital in Bologna for toxoplasmosis screening.All the sera were tested by Enzygnost toxoplasmosis IgG, Enzygnost toxoplasmosis IgM and Enzygnost system for IgA (Siemens Healthcare Diagnostics). Border-Line or positive IgM results were confirmed by Vidas Toxo IgM (bioMerieux, Marcy l’Etoile, France). Finally, IgG Avidity was performed by Vidas Toxo IgG Avidity (bioMerieux) and LDBio Toxoplasma WB IgG/IgM (LDBio Diagnostics, Lyon, France). During the study period, 453 sera were IgA negative, 53 were Border-Line and 85 were positive when tested by Enzygnost system for IgA. No significative correlation was found between IgA positive results and low Avidity results.Three babies were correctly diagnosed as congenital toxoplasmosis infected infants because of the presence of IgA antibodies at birth. Enzygnost system for IgA anti-Toxoplasma showed good diagnostic performances.We conclude that the high sensitivity and specificity of and its suitability for automation make it an ideal screening test.

In the last years the trend of centralizing small laboratories in large reference centers led to a careful evaluation of the diagnostic profiles. In the serology laboratory of Microbiology Unit, St. Orsola-Malpighi Hospital, Bologna, Italy the choice has been to combine random access analyzers (ARCHITECT Abbott) and ELISA analyzers (BEPIII Dade Behring).